Growth Hormone Replacement Therapy in Veterans with Gulf War Illness and GH Deficiency

Abstract

This study is a placebo-controlled, double-blind, parallel-group randomized clinical trial (RCT) of recombinant human growth hormone (rhGH) replacement therapy (using somatropin) vs. placebo in Veterans from Operations Desert Storm/Desert Shield with a history of Gulf War Illness (GWI) and adult growth hormone deficiency (AGHD). This study will assess the efficacy and safety of rhGH in this population, as well as treatment compliance. The primary hypothesis is that participants receiving rhGH for 6-months will show improvements in body composition (i.e., truncal fat mass reduction of 5.3% or greater) compared to placebo.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2022
Accession Number
AD1191317

Entities

People

  • Ricardo Jorge

Organizations

  • Baylor College of Medicine

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Abstracts
  • Alzheimer Disease
  • Biomedical Research
  • Body Composition
  • Clinical Trials
  • Deficiencies
  • Department Of Defense
  • Department Of Veterans Affairs
  • Diseases
  • Drug Therapy
  • Employment
  • Health Services
  • Hormones
  • Medical Personnel
  • Neoplasms
  • Pain
  • Persian Gulf Syndrome
  • Prostate Cancer
  • Quality Of Life
  • Therapy
  • Training

Fields of Study

  • Medicine

Readers

  • Gulf War Illness and Chronic Multisymptom Illness in Veterans.
  • Mental Health of Military Veterans with Posttraumatic Stress Disorder (PTSD): Risk Factors, Prevalence, Symptoms, and Treatment.